Beijing, China - Recently, the 34^th Great Wall International Congress of Cardiology (GW-ICC) was held in Beijing. Shanghai MicroPort EP MedTech Co., Ltd. (referred to as MicroPort EP) actively participated in the exhibition with FireMagic™ TrueForce™ Ablation Catheter (referred to as TrueForce™ Ablation Catheter) and IceMagic™ Cryoablation system, engaged experts in academic symposium. The symposium was co-hosted by professor Wenqing Zhu from Zhongshan Hospital of Fudan University, professor Xuebin Li from People’s Hospital of Peking University and professor Jin Xv from Tianjin Chest Hospital. During the symposium, two live demonstrations of atrial fibrillation procedures using TrueForce™ Ablation Catheter were presented, arouse follow-up discussions concerning force sensing technology and cryoablation technology among experts in attendance. It was noteworthy that pre-market clinical data and clinical trial of IceMagic™ Cryoablation system first published on this nationwide symposium, obtaining wide recognition from electrophysiologists and physicians.

The speakers, professor Rongfeng Zhang from First Affiliated Hospital of Dalian Medical University, professor Nian Liu from Beijing Anzhen Hospital and professor Mingyu Sun from Northern Military Hospital, specifically elaborated pre-market clinical data of TrueForce™ Ablation Catheter and IceMagic™ Cryoablation system, shared the atrial fibrillation treatment experience utilizing TrueForce™ Ablation Catheter.

In the first half of 2023, the pre-market clinical study results of TrueForce™ Ablation Catheter were first published in Pacing and Clinical Electrophysiology (PACE), covering 120 clinical application cases completed in five domestic tertiary hospitals. Professor Zhang Rongfeng, the physician from First Affiliated Hospital of Dalian Medical University, which is also the leading hospital in the pre-market clinical study of TrueForce™ Ablation Catheter, gave a detailed elaboration of the results and spoke highly of the ablation efficiency of the catheter.

Professor Liu Nian from Beijing Anzhen Hospital of Capital Medical University, introduced the structure and principles of TrueForce™ Ablation Catheter, as well as the components of Energy Index (EI). He believes that Energy Index can effectively indicate ablation lesions and the distance between ablation points. The force vector and force value display can further improve safety and efficacy of procedure. In addition, EasyStars™ High Density Mapping Catheter was approved to feature stable maneuverability and increase modeling efficiency.

Professor Mingyu Sun, the physician from Northern Military Hospital, which is also the leading hospital in the pre-market clinical study of IceMagic™ Cryoablation system, introduced the design principles, product features and clinical trial data. She said that the IceMagic™ Cryoablation Catheter features a novel design and excellent performance. In addition to the precise temperature control during cryoablation, some type of balloons supports unique multi-channel temperature monitoring and pressure monitoring, which can meet various surgical needs. Based on the clinical research results, among 159 atrial fibrillation procedures performed by using the IceMagic™ Cryoablation system in 8 centers, the immediate success rate was 100%, one-year-free rate of atrial ablation recurrence was as high as 81.94%. The data indicated a novel therapy for AF treatment.

More than 500 radiofrequency ablation procedures were successfully completed to date domestically by TrueForce™ Ablation Catheter. The approval of IceMagic™ Cryoablation system marks MicroPort EP’s achievement in providing radiofrequency ablation and cryoablation products.

In the future, MicroPort EP will continue to build an academic platform, conducting in-depth discussions with domestic and foreign electrophysiologists, forging ahead on the road of academic sharing and innovation.